Neonatal Respiratory Medicine
Ohb Neonatology Limited focuses on chronic lung disease in extremely premature infants, with particular attention to bronchopulmonary dysplasia and related respiratory complications in the neonatal period.
- Chronic lung disease
- Bronchopulmonary dysplasia
- Extremely premature babies
The sponsor’s research activity is centered on outcomes linked to severe respiratory morbidity and early-life survival in vulnerable newborn populations.
Perinatal and Neonatal Care
The clinical focus extends to the management of perinatal and neonatal complications associated with extreme prematurity, including conditions that affect lung development and respiratory stability after birth.
- Perinatal care
- Neonatal care
- Respiratory stability
Research interest is directed toward care settings where early respiratory support and long-term pulmonary health are central concerns.
Paediatric Pulmonary Outcomes
Its trial activity is aligned with paediatric pulmonary outcomes, especially measures that reflect the burden of persistent lung disease and the risk of severe respiratory impairment in infancy.
- Paediatric pulmonary outcomes
- Severe respiratory impairment
- Infant lung health
Attention is placed on clinical endpoints relevant to lung function, disease severity, and survival in the first weeks of life.
Therapeutic Development for Rare Infant Conditions
As a pharmaceutical company, the sponsor is involved in therapeutic development for a specialised rare disease setting, with work directed toward treatment options for neonatal respiratory disease in a highly vulnerable population.
- Rare disease therapeutics
- Neonatal treatment development
- Respiratory disease intervention
The research landscape reflects interest in interventions intended for infants at highest risk of chronic pulmonary complications.
